Merck’s Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer

A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half. New study results released Monday continue to cemen.....»»

Category: europeSource: fortuneApr 16th, 2018

Merck"s Keytruda meets main goal in pivotal lung cancer trial

(Reuters) - Merck & Co said on Monday a late-stage trial of its blockbuster cancer drug Keytruda met the main goal in helping previously untreated lung cancer patients live longer, sending its shares up 2.6 percent in premarket trade......»»

Category: topSource: reutersApr 9th, 2018

Merck"s Keytruda helps lung cancer patients live longer in trial

(Reuters) - Merck & Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market......»»

Category: topSource: reutersApr 9th, 2018

GlaxoSmithKline and Merck KGaA strike immunotherapy deal worth up to $4 billion

U.K.-based GlaxoSmithKline Plc  and Germany-based Merck KGaA are entering a partnership to develop and commercialize a therapy for patients with advanced non-small cell lung cancer in a deal worth up to $4.23 billion, the companies announced Tuesday......»»

Category: topSource: marketwatchFeb 5th, 2019

Merck Wins Big Against Rivals in Lung Cancer Study Survival Rates

Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates......»»

Category: blogSource: 247wallstApr 17th, 2018

Merck shares surge anew on lung cancer advance, while Bristol-Myers stock plummets

The pairing of Keytruda and chemotherapy reduced risk of death for patients with advanced lung cancer by half, a significant improvement......»»

Category: topSource: marketwatchApr 16th, 2018

"We are going to have lung cancer patients living longer and better:" A new kind of cancer treatment is about to change how we treat the disease (MRK, BMS)

Wikimedia Commons New cancer treatments that harness the body's immune system are ready to go mainstream.  In data presente.....»»

Category: topSource: businessinsiderApr 16th, 2018

This Lung Cancer Drug Could Let Patients Forgo Chemo—And It’s Sending Merck’s Stock Soaring

Merck gained.....»»

Category: europeSource: fortuneApr 9th, 2018

Merck"s Keytruda Gets EU Approval for Difficult Lung Cancer

Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer po.....»»

Category: worldSource: nytMar 15th, 2019

GSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy......»»

Category: topSource: reutersFeb 5th, 2019

Merck"s Keytruda Clinches CHMP Nod for Difficult Lung Cancer


Category: topSource: redinewsFeb 5th, 2019

Bristol-Myers Reports Higher Sales but Another Lung-Cancer Setback

Bristol-Myers Squibb said its fourth-quarter revenue rose on sales of key drugs, but it suffered another setback entering the market to treat newly diagnosed lung-cancer patients......»»

Category: smallbizSource: wsjJan 25th, 2019

Merck"s Keytruda Gets FDA Approval for Rare Skin Cancer

Merck (MRK) wins an accelerated approval from the FDA to expand Keytruda's label for the treatment of adult and pediatric patients with r.....»»

Category: smallbizSource: nytDec 20th, 2018

Merck KGaA and Pfizer say drug failed to meet primary endpoints in late-stage ovarian cancer trial

Merck KGaA and Pfizer Inc. said early Monday that the cancer immunotherapy avelumab did not meet the primary endpoints of a phase 3 ovarian cancer trial. The trial, JAVELIN Ovarian 200, teste.....»»

Category: topSource: marketwatchNov 19th, 2018

Why Merrimack Pharma Is Terminating Its Midstage Lung Cancer Study

Merrimack Pharmaceuticals shares dropped early on Friday after the company announced that it would be terminating its midstage SHERLOC study in patients with non-small cell lung cancer......»»

Category: blogSource: 247wallstOct 19th, 2018

A startup that"s helping us better understand the bugs that live in us just raised $83 million to start developing treatments for diseases like cancer

Courtesy Ubiome Microbiome startup uBiome, best known for its tests that sequence the bugs living in us, is expanding into drug development. Boosted by $83 million in series C funding, the San Francisc.....»»

Category: topSource: businessinsiderSep 21st, 2018

Your Cancer Highlight: Merck Tightening Its Grips On Front-Line Lung Cancer

Your Cancer Highlight: Merck Tightening Its Grips On Front-Line Lung Cancer.....»»

Category: topSource: seekingalphaSep 14th, 2018

Merck Gets Priority Review for Yet Another Keytruda sBLA

Merck's (MRK) sBLA to include overall survival data from a key lung cancer study on Keytruda's label gets .....»»

Category: smallbizSource: nytSep 13th, 2018

Atara Biotherapeutics Announces Second Quarter 2018 Financial Results and Recent Operational Progress

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, aut.....»»

Category: earningsSource: benzingaAug 1st, 2018

Merck"s Keytruda Gets Priority Review in Difficult Lung Cancer

Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decisio.....»»

Category: worldSource: nytJul 3rd, 2018

Merck"s (MRK) Keytruda Gets FDA Approval for Cervical Cancer

Merck's (MRK) Keytruda receives accelerated approval for the treatment of patients with advanced cervical cancer. Merck MRK has received FDA’s accelerated approval for label.....»»

Category: smallbizSource: nytJun 13th, 2018